Report Details:
15 Companies Covered
128 Pages
Oncology-based in vivo CRO Market Highlights
The Oncology-based in vivo CRO Market Size was estimated at 1.397 USD Billion in 2024. The Oncology-based in vivo CRO industry is projected to grow from 1.513 USD Billion in 2025 to 3.36 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.3% during the forecast period 2025 - 2035.
Growing cancer is predicted to enhance demand for therapies, as the disease's high burden fuels demand for outsourcing drug development activities, which is expected to further promote market growth during the projection period. It also shows that healthy lifestyles and public health action by governments and health practitioners can help to counteract this tendency, and cancer continues to be a promising driver of growth. Solid tumors are abnormal masses of tissue that grow as a result of cancer and impact numerous body parts such as organs, muscles, or bones.
Key Players
MRFR recognizes the following companies as the key players in the global oncology-based in vivo CRO market— Biosciences, Charles River Laboratory (CRL), Covance, Crown Bioscience, Eurofins Scientific, ICON Plc, Taconic, The Jackson Laboratory, Toxikon Inc., WuXi AppTe.
Segment Analysis
The global oncology-based in vivo CRO market has been segmented based indication and model.
On the basis of indication, the market is segmented into Blood cancer, Solid tumors, Others. The solid tumors segment was attributed to holding the largest market share in 2024 because it increased platelet which shortening survival boost tumors.
Based on model, the global oncology-based in vivo CRO market has been segmented into Syngeneic model, Xenograft. The syngeneic model segment was expected to hold the largest market share in 2024 because it increase the effect of vascular endothelial.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Oncology-based in vivo CRO Market Research Report
Regional Analysis
The global oncology-based in vivo CRO market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe oncology-based in vivo CRO market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The oncology-based in vivo CRO market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World oncology-based in vivo CRO market comprises of Middle East, Africa, and Latin America.
The largest market share for oncology-based in vivo CRO was maintained by the North American regional sector. This increase is attributed to expanding research and development for the region's market is likely to benefit from the region's high concentration of important companies, increased FDA approvals, strategic collaborations, and substantial investment in research & development activities. Because of increased cancer therapy usage and the expanding cancer burden in the United States, North America is likely to dominate the overall oncology-based In-Vivo CRO market over the projection period.
Moreover, the Europe market has been persistently growing over the forecast period. The demand for oncology-based in vivo CRO is driven by rising environmental consciousness and the establishment of strict environmental legislation. The market expansion is supported by an increasing healthcare infrastructure, economic development as a result of a rise in consumer preference for using sustainable energy sources.
Additionally, due to the Over the projection period, Asia Pacific is expected to display lucrative growth in the market for oncology-based in-vivo CRO. The presence of unexplored prospects, continually increasing healthcare infrastructure, economic development, and a large patient population are some of the elements responsible for the rapid expansion. This region is also ranked first in terms of ease of doing business. Furthermore, because to the availability of qualified staff and other resources, Asia Pacific would be the primary destination for in-vivo CRO initiatives.
Furthermore, the rest of the world's oncology-based in vivo CRO market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the region's rising use of electric vehicles and hydrogen production research and development. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.
Key Findings of the Study
The Oncology-based in vivo CRO Market is experiencing robust growth driven by technological advancements and the rising demand for personalized medicine.
- The rise of personalized medicine is reshaping treatment paradigms in oncology, particularly in North America.
- Technological advancements in research methods are improving the effectiveness of preclinical studies, especially in the Asia-Pacific region.
- Collaborations with academic institutions are accelerating drug development, notably in the blood cancer segment, which remains the largest segment.
- Rising cancer incidence and increased investment in oncology research are driving demand for outsourced preclinical studies, particularly in the solid tumors segment.
